查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2002839

血管成形術用氣球市場：依產品類型、適應症、銷售管道及最終用戶分類－2026-2032年全球市場預測

Angioplasty Balloons Market by Product Type, Indication, Sales Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，血管成形術用氣球市場價值將達到 44.8 億美元，到 2026 年將成長至 48.6 億美元，到 2032 年將達到 81.6 億美元，複合年成長率為 8.92%。

主要市場統計數據
基準年 2025 44.8億美元
預計年份：2026年 48.6億美元
預測年份 2032 81.6億美元
複合年成長率 (%) 8.92%

簡要概述器械創新、臨床證據的進步和採購審查如何重新定義血管成形術用氣球的戰略作用。

血管成形術用氣球仍然是經經皮心臟介入和周邊血管治療的核心，從常規手術到複雜的重組策略，無所不包。近年來，技術的進步和臨床證據的積累，使得器械的選擇不再僅僅是技術上的選擇，而是成為治療過程中的一個重要戰略環節，影響著手術的成功率、治療效果的持久性以及長期血管通暢率。如今，臨床醫師在評估球囊時，不僅考慮其標稱直徑和順應性，還會考慮藥物輸送特性、塗層均勻性以及在不同病變形態下的展開表現等輔助特性。

藥物輸送技術的進步、監管機構對真實世界臨床結果的重視以及供應鏈需求，正在如何改變醫療器材的採用趨勢？

血管成形術用氣球市場正經歷一系列變革性變化，這些變化正在全面改變器械的研發、上市和報銷方式。首先，藥物輸送技術的成熟使臨床討論從單純的機械擴張擴展到針對血管再阻塞生物機制的綜合療法。這種技術轉變促使製造商加強對塗層化學、賦形劑選擇和輸送均勻性的投入，以提升臨床療效。其次，監管機構對真實世界數據和上市後監測的重視提高了長期安全性和有效性監測的標準，促使供應商將證據生成納入其產品上市策略。

評估採購行為對 2025 年關稅政策下供應鏈重組、採購決策、醫療設備的供應和成本結構的影響。

2025年關稅政策的變化為血管成形術用氣球的製造商、經銷商和買家帶來了新的考量，增加了本已錯綜複雜的供應鏈的成本和營運難度。由於部分醫療設備的進口關稅上調，許多供應商重新審視了其生產地點、籌資策略以及與全球合作夥伴的合約條款。為此，一些製造商探索了近岸外包方案、多元化零件採購管道，並與供應商重新談判契約，以緩解利潤壓力並維持臨床應用的穩定供應。

產品類型、臨床適應症和醫療保健環境細分如何揭示血管成形術用氣球。

細分市場分析突顯了產品設計、臨床適應症和終端用戶環境如何共同構成血管成形術用氣球的競爭格局。從產品角度來看，市場分為藥物塗層球囊和普通球囊，這種區分導致了不同的證據要求、採購標準和臨床應用模式。藥物塗層技術在血管再阻塞風險是主要關注點的情況下尤其值得關注，而普通球囊在處理較簡單的病變或優先考慮手術成本效益的醫療機構中仍然發揮著重要作用。從適應症來看，市場分為冠狀動脈應用和周邊血管應用，其中周邊血管應用又細分為頸動脈、髂動脈、下肢動脈和腎動脈。這些不同的解剖標靶需要不同的尺寸、順應性和輸送特性，因此，針對特異性病變的設計考量和操作者訓練顯得特別重要。

美洲、歐洲、中東和非洲以及亞太地區的區域採納因素和採購趨勢決定了臨床引進和商業化的途徑。

區域趨勢表明，報銷框架、臨床實踐模式和法規環境如何相互作用，共同塑造區域需求和應用路徑。在美洲，臨床網路和醫療設備經銷商在製定處方集和確保器械選擇符合醫療通訊協定發揮主導作用。成熟的心臟導管介入基礎設施能夠快速吸收分階段推出的醫療設備創新，這些創新均有強而有力的臨床證據和清晰的採購價值提案作為支撐。在歐洲、中東和非洲（EMEA），由於法規環境和保險報銷機制的差異，各地區的應用進度有所不同。有些國家優先考慮集中採購，而有些國家則允許更多本地決策，這影響新技術應用的步伐。

深入了解臨床證據、製造夥伴關係和差異化商業性能力如何決定醫療設備製造商的競爭地位。

製造商之間的競爭動態反映了技術差異化、臨床證據的累積和商業性可行性之間的平衡。主要企業正投資於塗層技術、部署精度和臨床試驗項目，以支持其關於改善血管通暢性和減少再次干預需求的說法。同時，一些靈活的小型製造商則專注於小眾適應症和具有成本競爭力的普通球囊產品，以服務對價格敏感的大批量管道。隨著企業尋求擴大生產規模，同時為研發和上市後監測籌集資金，醫療設備製造商與契約製造製造商之間的策略合作也日益普遍。

採取切實可行的策略行動，整合證據產生、供應鏈韌性和商業性提案，以促進採納並降低營運風險。

產業領導者應優先考慮一系列切實可行的舉措，將臨床檢驗、營運韌性和商業性透明度相結合，以獲得永續的競爭優勢。投資於有針對性的真實世界數據 (REW) 項目，以補充隨機試驗並展示設備在常規臨床環境中的表現。這些數據將有助於與臨床醫生和保險公司就產品推廣應用進行討論。同時，透過多元化零件來源、探索區域生產方案以及協商降低關稅和物流中斷風險的合約條款，增強供應鏈的柔軟性。這些措施將有助於在確保產品供應的同時，維持利潤率的穩定。

採用嚴謹的多面向研究途徑，整合臨床文獻回顧、監管分析、專家訪談和供應鏈評估，以獲得可靠的見解。

本分析的研究結合了對同行評審的臨床文獻、監管文件和公開指南的系統性回顧，以及對醫療設備製造商、臨床負責人和採購負責人的結構化專家訪談和初步定性研究。在評估臨床證據時，優先考慮隨機對照試驗、註冊資料和嚴格控制的觀察性研究，以了解不同器械類型和適應症的表現特徵。此外，還仔細審查了監管文件和上市後安全通告，以識別影響商業策略的標籤、不利事件報告和監測要求的趨勢。

創新整合、對證據的需求以及供應的韌性是影響血管成形術用氣球。

總之，血管成形術用氣球的市場格局正從專注於機械擴張轉向更廣泛的模式，整合藥物輸送、手術相容性和運作可靠性。這項轉變的驅動力來自塗層技術的進步、對真實世界數據日益成長的需求以及醫療系統內日益完善的採購方式。關稅波動和供應鏈壓力使得生產和採購決策變得更加緊迫，促使製造商重新評估生產地點並加強與大規模醫療機構的貿易關係。按產品類型、解剖適應症和最終用戶環境進行細分，凸顯了客製化產品設計和通路策略的必要性，這些策略應反映各自的臨床和採購重點。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：血管成形術用氣球市場：依產品類型分類

  • 冠狀動脈成形術球囊
    • 標準（半相容）氣球
    • 不合規的氣球
    • 藥物塗層氣球
    • 切割和劃線氣球
  • 周邊血管生成球囊
    • 藥物塗層周邊球囊
    • 高壓外周球囊
    • 特殊末梢用球囊
  • 神經血管球囊
    • 改造氣球
    • 閉塞球囊

第9章：血管成形術用氣球市場：依適應症分類

  • 冠狀動脈
  • 外圍
    • 頸動脈
    • 髂骨
    • 下肢
    • 腎

第10章：血管成形術用氣球市場：依銷售管道分類

  • 直銷
  • 透過批發商和零售商進行銷售
    • 大型批發商網路
    • 獨立經銷商網路
  • 線上和電子採購

第11章：血管成形術用氣球市場：依最終用戶分類

  • 門診手術中心
  • 心臟中心
  • 醫院
  • 專科診所

第12章：血管成形術用氣球：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：血管成形術用氣球市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章血管成形術用氣球市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國血管成形術用氣球市場

第16章：中國血管成形術用氣球市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Acrostak Int. Distr. Sarl
  • AngioDynamics, Inc.
  • B. Braun SE
  • Becton, Dickinson and Company
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • Cook Group Incorporated
  • Cordis
  • CSI
  • Hexacath
  • InSitu Technologies Inc.
  • Koninklijke Philips NV
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Medtronic PLC
  • Merit Medical Systems, Inc.
  • MicroPort Scientific Corporation
  • Nipro Medical Corporation
  • PALEX MEDICAL, SA
  • phenox GmbH
  • Scitech Medical
  • Teleflex Incorporated.
  • Terumo Medical Corporation
Product Code: MRR-957C47F90693

The Angioplasty Balloons Market was valued at USD 4.48 billion in 2025 and is projected to grow to USD 4.86 billion in 2026, with a CAGR of 8.92%, reaching USD 8.16 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.48 billion
Estimated Year [2026] USD 4.86 billion
Forecast Year [2032] USD 8.16 billion
CAGR (%) 8.92%

A concise framing of how device innovation, clinical evidence evolution, and procurement scrutiny are redefining the strategic role of angioplasty balloons

Angioplasty balloons remain central to percutaneous interventional cardiology and peripheral vascular care, underpinning both routine procedures and complex revascularization strategies. Over recent years, technological refinement and iterative clinical evidence have elevated device selection from a purely technical choice to a strategic component of care pathways, influencing procedural success, durability of outcomes, and long-term vessel patency. Clinicians increasingly evaluate balloons not only on nominal diameter and compliance but on adjunctive attributes such as drug delivery profile, coating uniformity, and deployment behavior under varied lesion morphologies.

Concurrently, health systems and payers are intensifying scrutiny of procedure value, which has shifted procurement conversations toward devices that demonstrate consistent clinical performance, reduce complication rates, and streamline supply chain management. Regulatory evolution and the accumulation of real-world evidence are reshaping labeling and post-market surveillance expectations, while centers of excellence focus on protocol standardization to reduce variability in outcomes. Together, these dynamics set the stage for a nuanced market environment in which clinical differentiation, operational compatibility, and cost containment coalesce to determine device adoption.

How advancements in drug-delivery technology, regulatory emphasis on real-world outcomes, and supply chain demands are transforming device adoption dynamics

The angioplasty balloon landscape is being reshaped by a series of transformative shifts that are collectively altering how devices are developed, adopted, and reimbursed. First, the maturation of drug delivery technologies has broadened clinical conversations from purely mechanical dilation to integrated therapy that addresses restenosis biology. This technological pivot has prompted manufacturers to invest in coating chemistry, excipient selection, and delivery uniformity to differentiate clinical performance. Second, regulatory emphasis on real-world data and post-market surveillance has increased the bar for longitudinal safety and effectiveness monitoring, motivating vendors to build evidence generation into product launch strategies.

Third, supply chain resilience and cost transparency have emerged as operational priorities for health systems, accelerating interest in vendor consolidation, standardized device formularies, and bundled procurement agreements. Fourth, procedural innovation-such as hybrid approaches that combine adjunctive atherectomy or imaging-guided lesion preparation-has elevated the importance of device compatibility across diverse treatment workflows. Taken together, these shifts are driving a more integrated, evidence-driven, and system-aware market where clinical utility, operational fit, and lifecycle support determine long-term adoption trajectories.

Assessment of the 2025 tariff-driven recalibration of supply chains, sourcing decisions, and procurement behavior affecting device availability and cost structures

Tariff policy changes in 2025 imposed new considerations for manufacturers, distributors, and purchasers of angioplasty balloons, introducing cost and operational complexity into already intricate supply chains. Increased import levies on certain classes of medical devices prompted many suppliers to reassess production footprints, sourcing strategies, and contractual terms with global partners. In response, several manufacturers explored nearshoring options, diversified component sourcing, and renegotiated supplier contracts to mitigate margin pressure and maintain stable supply to clinical customers.

Health systems and purchasing groups responded by accelerating vendor rationalization and by seeking more transparent landed-cost models to predict procedural expenses. Some institutions prioritized agreements that provided price protection and inventory support to blunt short-term volatility. The tariff-induced recalibration also spurred a renewed focus on device standardization across procedural suites to reduce SKU complexity and administrative burden. Importantly, these adjustments were not solely financial; they influenced commercialization timelines, product launch sequencing, and strategic partnerships as firms balanced regulatory compliance, manufacturing flexibility, and the imperative to sustain clinical availability.

How product type, clinical indication, and care setting segmentation reveal distinct clinical, procurement, and commercialization imperatives for angioplasty balloons

Segmentation insight highlights how product design, clinical indication, and end-user environment collectively shape the competitive dynamics for angioplasty balloons. Based on Product, market is studied across Drug Coated Balloon and Plain Balloon, and that distinction drives different evidence needs, purchasing criteria, and clinical adoption patterns; drug-coated technologies command particular attention where restenosis risk is a central concern, whereas plain balloons retain importance for simpler lesions and for centers prioritizing procedural cost efficiency. Based on Indication, market is studied across Coronary and Peripheral, with the Peripheral category further studied across Carotid, Iliac, Lower Limb, and Renal; these divergent anatomical targets require tailored sizing, compliance characteristics, and delivery profiles, elevating the role of lesion-specific design considerations and operator training.

Based on End User, market is studied across Ambulatory Surgical Centers, Cardiac Centers, Hospitals, and Specialty Clinics, and the purchasing priorities across these settings vary markedly. Ambulatory surgical centers emphasize throughput, predictable inventory, and cost-effective device selection, while cardiac centers and hospitals balance high-acuity capability with multi-disciplinary procurement processes that factor in clinical preference, support services, and educational partnerships. Specialty clinics often prioritize niche devices optimized for targeted peripheral interventions and may favor vendors that can provide focused clinical training and flexible procurement terms. Recognizing these intersecting segmentation lenses is essential for product positioning and channel strategy.

Regional adoption drivers and procurement behaviors across the Americas, EMEA, and Asia-Pacific that determine clinical uptake and commercialization pathways

Regional dynamics demonstrate how reimbursement frameworks, clinical practice patterns, and regulatory climates interact to shape demand and adoption pathways across geographies. In the Americas, clinical networks and device distributors play a dominant role in establishing formularies and in aligning device selection with institutional protocols; a mature interventional cardiology infrastructure supports rapid assimilation of incremental device innovations when supported by robust clinical evidence and clear procurement value propositions. In Europe, Middle East & Africa, divergent regulatory environments and heterogeneous reimbursement mechanisms create a patchwork of adoption timelines, with some national systems emphasizing centralized procurement and others allowing more localized decision-making, which in turn affects the pace at which new technologies are adopted.

In Asia-Pacific, rapid investments in vascular care capacity combined with growing local manufacturing capabilities are reshaping competitive dynamics; several markets within the region are prioritizing technology transfer and local regulatory approvals to reduce import dependencies. Across all regions, cross-border partnerships, regional clinical investigators, and localized evidence generation are decisive factors that influence how quickly clinicians incorporate new balloon technologies into treatment algorithms and how purchasing organizations evaluate supplier commitments to training and supply continuity.

Insights into how clinical evidence, manufacturing partnerships, and differentiated commercial capabilities determine competitive positioning among device manufacturers

Competitive dynamics among manufacturers reflect a balance between technological differentiation, clinical evidence generation, and commercial execution. Leading firms invest in coating science, deployment precision, and clinical trial programs to substantiate claims of improved vessel patency or reduced need for repeat interventions. At the same time, a cohort of agile, smaller manufacturers focuses on niche indications or cost-competitive plain balloon offerings that serve high-volume, price-sensitive channels. Strategic alliances between device makers and contract manufacturers have also become more common as firms seek to scale production while preserving capital for R&D and post-market studies.

Commercial capabilities-including clinician education programs, local regulatory expertise, and integrated supply solutions-shape market access nearly as much as product features in many settings. Manufacturers that align clinical KOL engagement with comprehensive real-world outcome tracking tend to gain sustained preference among large health systems. Moreover, companies that offer logistical flexibility, training partnerships, and responsive field support can mitigate barriers to switching and can accelerate adoption in settings where procedural volume and institutional inertia otherwise slow uptake.

Practical strategic actions that synchronize evidence generation, supply chain resilience, and commercial propositions to enhance adoption and mitigate operational risk

Industry leaders should prioritize a set of pragmatic actions that align clinical validation, operational resilience, and commercial clarity to capture sustainable advantage. Invest in targeted real-world evidence programs that complement randomized studies and demonstrate device performance across routine practice environments; such data supports adoption conversations with both clinicians and payers. Simultaneously, strengthen supply chain flexibility by diversifying component sources, exploring regional manufacturing options, and negotiating contractual provisions that reduce exposure to tariff and logistics shocks. These steps will protect availability while preserving margin stability.

Commercially, refine value propositions by linking clinical outcomes to total procedural cost and care pathway efficiency, and design pricing strategies that reflect predictable landed costs for institutional buyers. Enhance customer intimacy through training initiatives, field support, and clinician-led education to lower switching barriers. Finally, pursue selective partnerships with outpatient centers and specialty clinics to broaden route-to-market channels and to pilot new procedural protocols that can later scale into larger hospital systems. Together, these actions align product innovation with the operational needs of purchasers and the clinical priorities of users.

A rigorous multi-source research approach integrating clinical literature review, regulatory analysis, expert interviews, and supply chain assessment for robust insights

The research for this analysis combined a structured review of peer-reviewed clinical literature, regulatory filings, and publicly available guidance with structured expert interviews and primary qualitative outreach to device manufacturers, clinician leaders, and procurement professionals. Clinical evidence appraisal prioritized randomized trials, registry data, and carefully controlled observational studies to understand performance characteristics across device types and anatomical indications. Regulatory documentation and post-market safety notices were examined to identify trends in labeling, adverse event reporting, and surveillance expectations that affect commercial strategy.

Primary qualitative research included in-depth interviews with interventional cardiologists, peripheral vascular specialists, procurement directors, and device commercialization experts to surface practical considerations around device selection, training needs, and inventory management. Supply chain assessment drew on supplier disclosures, manufacturing footprint analyses, and industry commentary to map sourcing vulnerabilities and response strategies. Finally, cross-validation was performed by triangulating qualitative inputs with the clinical literature and regulatory records to ensure findings are robust, actionable, and reflective of current industry realities.

Synthesis of innovation, evidence demands, and supply resilience as the primary forces shaping strategic decisions in the angioplasty balloon domain

In conclusion, the angioplasty balloon landscape is evolving from a focus on mechanical dilation to a broader paradigm that integrates drug delivery, procedural compatibility, and operational reliability. This evolution is driven by advances in coating technologies, heightened expectations for real-world evidence, and increasing procurement sophistication among health systems. Tariff shifts and supply chain pressures have injected urgency into manufacturing and sourcing decisions, prompting manufacturers to reconsider production geographies and to strengthen commercial terms with large institutional buyers. Segmentation across product type, anatomical indication, and end-user setting underscores the need for tailored product designs and channel strategies that reflect distinct clinical and purchasing priorities.

Regional dynamics further complicate the pathway to adoption, with differing regulatory and reimbursement landscapes requiring localized evidence and market approaches. Competitive differentiation now hinges as much on evidence, clinician engagement, and supply assurance as it does on incremental device features. For decision-makers, the imperative is clear: align innovation with demonstrable clinical impact, secure resilient supply and transparent pricing, and invest in clinician and purchaser partnerships that accelerate safe, effective adoption of new device technologies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Angioplasty Balloons Market, by Product Type

  • 8.1. Coronary Angioplasty Balloons
    • 8.1.1. Standard (Semi-Compliant) Balloons
    • 8.1.2. Non-Compliant Balloons
    • 8.1.3. Drug-Coated Balloons
    • 8.1.4. Cutting and Scoring Balloons
  • 8.2. Peripheral Angioplasty Balloons
    • 8.2.1. Drug-Coated Peripheral Balloons
    • 8.2.2. High-Pressure Peripheral Balloons
    • 8.2.3. Specialty Peripheral Balloons
  • 8.3. Neurovascular Balloons
    • 8.3.1. Remodeling Balloons
    • 8.3.2. Occlusion Balloons

9. Angioplasty Balloons Market, by Indication

  • 9.1. Coronary
  • 9.2. Peripheral
    • 9.2.1. Carotid
    • 9.2.2. Iliac
    • 9.2.3. Lower Limb
    • 9.2.4. Renal

10. Angioplasty Balloons Market, by Sales Channel

  • 10.1. Direct Sales
  • 10.2. Distributor and Dealer Sales
    • 10.2.1. Large-Scale Distributor Networks
    • 10.2.2. Independent Dealer Networks
  • 10.3. Online and E-Procurement

11. Angioplasty Balloons Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cardiac Centers
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Angioplasty Balloons Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Angioplasty Balloons Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Angioplasty Balloons Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Angioplasty Balloons Market

16. China Angioplasty Balloons Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Acrostak Int. Distr. Sarl
  • 17.7. AngioDynamics, Inc.
  • 17.8. B. Braun SE
  • 17.9. Becton, Dickinson and Company
  • 17.10. BIOTRONIK SE & Co. KG
  • 17.11. Boston Scientific Corporation
  • 17.12. Cardinal Health, Inc.
  • 17.13. Cook Group Incorporated
  • 17.14. Cordis
  • 17.15. CSI
  • 17.16. Hexacath
  • 17.17. InSitu Technologies Inc.
  • 17.18. Koninklijke Philips N.V
  • 17.19. Lepu Medical Technology(Beijing)Co., Ltd.
  • 17.20. Medtronic PLC
  • 17.21. Merit Medical Systems, Inc.
  • 17.22. MicroPort Scientific Corporation
  • 17.23. Nipro Medical Corporation
  • 17.24. PALEX MEDICAL, S.A.
  • 17.25. phenox GmbH
  • 17.26. Scitech Medical
  • 17.27. Teleflex Incorporated.
  • 17.28. Terumo Medical Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANGIOPLASTY BALLOONS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANGIOPLASTY BALLOONS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANGIOPLASTY BALLOONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANGIOPLASTY BALLOONS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY STANDARD (SEMI-COMPLIANT) BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY STANDARD (SEMI-COMPLIANT) BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY STANDARD (SEMI-COMPLIANT) BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY NON-COMPLIANT BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY NON-COMPLIANT BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY NON-COMPLIANT BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY DRUG-COATED BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY DRUG-COATED BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY DRUG-COATED BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY CUTTING AND SCORING BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY CUTTING AND SCORING BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY CUTTING AND SCORING BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY DRUG-COATED PERIPHERAL BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY DRUG-COATED PERIPHERAL BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY DRUG-COATED PERIPHERAL BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY HIGH-PRESSURE PERIPHERAL BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY HIGH-PRESSURE PERIPHERAL BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY HIGH-PRESSURE PERIPHERAL BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY SPECIALTY PERIPHERAL BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY SPECIALTY PERIPHERAL BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY SPECIALTY PERIPHERAL BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY REMODELING BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY REMODELING BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY REMODELING BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY OCCLUSION BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY OCCLUSION BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY OCCLUSION BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY CAROTID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY CAROTID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY CAROTID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY ILIAC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY ILIAC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY ILIAC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY LOWER LIMB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY LOWER LIMB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY LOWER LIMB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY RENAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY RENAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY RENAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY LARGE-SCALE DISTRIBUTOR NETWORKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY LARGE-SCALE DISTRIBUTOR NETWORKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY LARGE-SCALE DISTRIBUTOR NETWORKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY INDEPENDENT DEALER NETWORKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY INDEPENDENT DEALER NETWORKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY INDEPENDENT DEALER NETWORKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY ONLINE AND E-PROCUREMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY ONLINE AND E-PROCUREMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY ONLINE AND E-PROCUREMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ANGIOPLASTY BALLOONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ANGIOPLASTY BALLOONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS ANGIOPLASTY BALLOONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS ANGIOPLASTY BALLOONS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ANGIOPLASTY BALLOONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ANGIOPLASTY BALLOONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ANGIOPLASTY BALLOONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ANGIOPLASTY BALLOONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ANGIOPLASTY BALLOONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ANGIOPLASTY BALLOONS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ANGIOPLASTY BALLOONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ANGIOPLASTY BALLOONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ANGIOPLASTY BALLOONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ANGIOPLASTY BALLOONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ANGIOPLASTY BALLOONS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ANGIOPLASTY BALLOONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ANGIOPLASTY BALLOONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ANGIOPLASTY BALLOONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ANGIOPLASTY BALLOONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ANGIOPLASTY BALLOONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC ANGIOPLASTY BALLOONS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ANGIOPLASTY BALLOONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ANGIOPLASTY BALLOONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ANGIOPLASTY BALLOONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ANGIOPLASTY BALLOONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ANGIOPLASTY BALLOONS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN ANGIOPLASTY BALLOONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ANGIOPLASTY BALLOONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ANGIOPLASTY BALLOONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ANGIOPLASTY BALLOONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ANGIOPLASTY BALLOONS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, 2018-2032 (USD MILLION)
  • TABLE 193. GCC ANGIOPLASTY BALLOONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ANGIOPLASTY BALLOONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ANGIOPLASTY BALLOONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ANGIOPLASTY BALLOONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION ANGIOPLASTY BALLOONS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ANGIOPLASTY BALLOONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ANGIOPLASTY BALLOONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ANGIOPLASTY BALLOONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ANGIOPLASTY BALLOONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS ANGIOPLASTY BALLOONS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ANGIOPLASTY BALLOONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ANGIOPLASTY BALLOONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ANGIOPLASTY BALLOONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 218. G7 ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 219. G7 ANGIOPLASTY BALLOONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 221. G7 ANGIOPLASTY BALLOONS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. G7 ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, 2018-2032 (USD MILLION)
  • TABLE 223. G7 ANGIOPLASTY BALLOONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ANGIOPLASTY BALLOONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO ANGIOPLASTY BALLOONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 228. NATO ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 229. NATO ANGIOPLASTY BALLOONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 230. NATO ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 231. NATO ANGIOPLASTY BALLOONS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. NATO ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ANGIOPLASTY BALLOONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL ANGIOPLASTY BALLOONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES ANGIOPLASTY BALLOONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES ANGIOPLASTY BALLOONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES ANGIOPLASTY BALLOONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES ANGIOPLASTY BALLOONS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ANGIOPLASTY BALLOONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA ANGIOPLASTY BALLOONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA ANGIOPLASTY BALLOONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA ANGIOPLASTY BALLOONS MARKET SIZE, BY CORONARY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA ANGIOPLASTY BALLOONS MARKET SIZE, BY NEUROVASCULAR BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA ANGIOPLASTY BALLOONS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA ANGIOPLASTY BALLOONS MARKET SIZE, BY PERIPHERAL, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA ANGIOPLASTY BALLOONS MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA ANGIOPLASTY BALLOONS MARKET SIZE, BY DISTRIBUTOR AND DEALER SALES, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA ANGIOPLASTY BALLOONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)